CClinicalTrials.gg
RecruitingNCT07188038INFLATE-ICUUpdated Sep 2, 2026

The Impact of Low Versus High Positive End-expiratory Pressure on Diaphragm Function, Ventilation Efficiency, and Lung Mechanics

An interventional study of Low positive end-expiratory pressure and Medium positive end-expiratory pressure in Respiratory Failure, ARDS (Acute Respiratory Distress Syndrome) and Pneumonia, sponsored by Vastra Gotaland Region. Recruiting at 2 sites in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-02.

Sponsored by Vastra Gotaland Region · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Started Aug 2026; still recruiting 1 month later.
Phase
Not applicable
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this interventional study is to evaluate the effect of different positive end-expiratory pressures (PEEP) on lung and diaphragm function in patients mechanically ventilated with pressure support ventilation in the intensive care unit. The main questions aim to answer:

Does higher PEEP level affect diaphragm contractions and ventilatory efficiency? Does higher PEEP level limit inspiratory efforts? Does higher PEEP level affect lung compliance?

The participants will be subjected to three different PEEP levels during pressure support ventilation:

Low PEEP (4 cmH2O), Medium PEEP (10 cmH2O), High PEEP (16 cmH2O).

The lung and diaphragm function will be evaluated using high-resolution esophageal manometry, electrical activity of the diaphragm, external diaphragm ultrasound and spirometric ventilator data.

02

Conditions studied

  • Respiratory Failure
  • ARDS (Acute Respiratory Distress Syndrome)
  • Pneumonia
  • Respiratory Insufficiency

Keywords

  • Positive end-expiratory pressure
  • PEEP
  • pressure support ventilation
  • assisted breathing
  • Inspiratory effort
  • Inspiratory drive
  • Ventilation efficiency
  • Diaphragm
03

In context

Respiratory Insufficiency

1,650 studies on the registry are indexed under Respiratory Insufficiency; 296 are open to participants now.

This study's planned enrollment of 25 is below the median of 55 across 1,043 interventional studies indexed under Respiratory Insufficiency.

Browse Respiratory Insufficiency studies →

Lead sponsor

Vastra Gotaland Region is the lead sponsor of 267 studies on the registry; 107 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Mechanical ventilation with pressure support or mechanical ventilation with possibility to transition to pressure support
  • Oxygen requirement ≤ 50%
  • Pressure support ≤ 12 cmH2O
  • PEEP ≤ 12 cmH2O
  • Age ≥ 18 years
  • Adequate intravascular volume status

Exclusion criteria

Exclusion Criteria:

  • Circulatory instability
  • Brain death diagnosis/brain death evaluation
  • Norepinephrine dose > 0.4 µg/kg/min
  • Muscle relaxation administered within 2 hours
  • Pregnancy
  • Contraindication to esophageal catheterization (e.g., esophageal varices)
  • Conditions with increased risk of pneumothorax (such as severe COPD (Chronic Obstructive Pulmonary Disease) or extensive emphysema)
  • Untreated pneumothorax
  • Symptomatic airway obstruction

Discontinuation criteria during ongoing study intervention:

  • Heart rate > 120 beats/min
  • Systolic blood pressure > 180 mmHg
  • Inspired oxygen fraction > 70%
  • Respiratory rate > 35/min
  • RASS (Richmond Agitation Sedation Scale) ≥ 2
  • Doubling of norepinephrine dose or increase of norepinephrine dose to > 0.5 µg/kg/min to maintain mean arterial pressure
  • Bradycardia \< 45 beats/min
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
25 participants (estimated)

Study arms

  • Experimental
    Low PEEP

    Low positive end-expiratory pressure (4 cmH2O)

    Procedure: Low positive end-expiratory pressure

  • Experimental
    Medium PEEP

    Medium positive end-expiratory pressure (10 cmH2O)

    Procedure: Medium positive end-expiratory pressure

  • Experimental
    High PEEP

    High positive end-expiratory pressure (16 cmH2O)

    Procedure: High positive end-expiratory pressure

Interventions

  • ProcedureLow positive end-expiratory pressure

    Low (4 cmH2O) positive end-expiratory pressure (PEEP) will be applied during pressure support ventilation. The PEEP level will be kept for 10 minutes prior to data acquisition.

  • ProcedureMedium positive end-expiratory pressure

    Medium (10 cmH2O) positive end-expiratory pressure (PEEP) will be applied during pressure support ventilation. The PEEP level will be kept for 10 minutes prior to data acquisition.

  • ProcedureHigh positive end-expiratory pressure

    High(16 cmH2O) positive end-expiratory pressure (PEEP) will be applied during pressure support ventilation. The PEEP level will be kept for 10 minutes prior to data acquisition.

06

What researchers measure

Primary outcomes

  1. Inspiratory effort

    Inspiratory effort will be measured by the tidal change in esophageal pressure (in cmH2O) during assisted breathing. The esophageal pressure will be measured using a high-resolution manometry catheter. The change from expiratory to inspiratory esophageal pressure will represent the tidal change and be used to estimate the inspiratory effort.

    Time frame: Measured during 5 uninterrupted breaths 10 minutes after application of interventional PEEP level

  2. Inspiratory drive

    The electric activity of the diaphragm (Eadi) will be measured using a NAVA (neurally adjusted ventilatory assist) catheter. The change from end-expiratory to inspiratory Eadi will be calculated. This represents the inspiratory drive. The Eadi will be measured in Voltage.

    Time frame: Measured during 5 uninterrupted breaths 10 minutes after application of interventional PEEP level

  3. Effort-to-drive ratio

    The effort-to-drive ratio (EDR) will be calculated as the inspiratory effort (tidal change in esophageal pressure) divided by the inspiratory drive (tidal change in electric activity of the diaphragm).

    Time frame: Calculated from the measures collected 10 minutes after application of interventional PEEP level

  4. Neuromechanical efficiency

    The neuromechanical efficiency will be calculated as the change in airway pressure during an occlusion test (Pocc) (measured from end-expiration to maximum negative pressure during the occlusion manoeuvre) divided by the inspiratory change in electric activity of the diaphragm (from end-expiration to inspiration).

    Time frame: Calculated from the measures collected during the occlusion manoeuvre performed 10-15 minutes after application of interventional PEEP level

  5. Thickening fraction of the diaphragm (TFdi)

    Measured by ultrasound at the right hemidiaphragm. The thickening fraction of the diaphragm (TFdi) will be calculated as \[ (end-inspiratory diaphragm thickness - end-expiratory diaphragm thickness) / end-expiratory diaphragm thickness) \].

    Time frame: Measured 10 minutes after application of interventional PEEP level

  6. Transpulmonary driving pressure

    Change in transpulmonary pressure ( airway pressure - esophageal pressure) from end-expiration to end-inspiration will be calculated using ventilator data and high-resolution manometry

    Time frame: Measured during 5 breaths 10 minutes after application of interventional PEEP level

  7. Occlusion pressure

    The airway pressure drop from end-expiration to minimum pressure during an occlusion manoeuvre will be measured using the ventilator. The pressure drop indicates the inspiratory effort. It will be measured in cmH2O.

    Time frame: The occlusion pressure will be measured during an occlusion manoeuvre performed 10-15 minutes after application of interventional PEEP level.

Secondary outcomes

  1. Airway driving pressure

    Difference in airway pressure between end-expiration and during an inspiratory hold will be calculated from the ventilator data.

    Time frame: Measured during an inspiratory hold performed 10-15 minutes after application of interventional PEEP level

  2. Lung compliance

    Lung compliance will be calculated as the tidal volume divided by the change in transpulmonary pressure from end-expiration to end-inspiration.

    Time frame: Measured during an inspiratory hold performed 10 - 15 minutes after application of interventional PEEP level

  3. Thickening fraction of the expiratory abdominal muscles (TFabd)

    The abdominal muscles will be visualized by ultrasound in the anterior axillary line, midway between the inferior border of the ribcage and the iliac crest. The thickening fraction will be calculated as \[(expiratory thickness - end-inspiratory thickness) / end-inspiratory thickness \].

    Time frame: Measured 10 minutes after application of interventional PEEP level

  4. Oxygenation

    The PFI (PaO2/FiO2 ratio) will be calculated as arterial PaO2 (partial pressure of oxygen) divided by the FiO2 (fraction of inspired oxygen)

    Time frame: The blood gas will be collected 10 minutes after application of interventional PEEP level

  5. Respiratory system compliance

    The respiratory system compliance will be calculated as the tidal volume divided by the airway driving pressure during an inspiratory hold.

    Time frame: Measured during an inspiratory hold manoeuvre performed 10-15 minutes after the application of interventional PEEP level.

Other outcomes

  1. Central venous oxygen saturation (ScvO2)

    Oxygen saturation of venous blood drawn from a central venous catheter.

    Time frame: Venous blood gas will be collected 10 minutes after application of interventional PEEP level

  2. Tidal volume

    The volume change from end-expiration to end-inspiration. Will be acquired from the ventilator.

    Time frame: Measured in 5 breaths 10 minutes after the application of interventional PEEP level.

  3. Respiratory rate

    The number of breaths per minutes (respiratory rate) will be calculated from the volume-time curve acquired from the ventilator.

    Time frame: Measured 10 minutes after the application of interventional PEEP level.

  4. Dead space

    Dead space (volume of gas not participating in gas exchange) will be calculated from the difference between arterial and end-expiratory partial pressure of Carbon dioxide, using blood gas analysis and capnography.

    Time frame: The dead space will be calculated 10 minuted after application of interventional PEEP level.

  5. Change in end-expiratory lung volume

    The change in end-expiratory lung volume will be calculated as the accumulated difference in inspired and expired gas volume during the first 15 breaths after a PEEP change. This will be acquired using the ventilator.

    Time frame: Measured in the 15 breaths following a PEEP change.

  6. End-expiratory diaphragm thickness

    The end-expiratory diaphragm thickness will be measured by ultrasound as the thickness of the diaphragm at the right hemisphere at end-expiration.

    Time frame: This will be measured during end-expiration 10 minutes after the application of interventional PEEP level.

  7. Neuroventilatory efficiency

    The neuroventilatory efficiency will be calculated as the tidal volume divided by the change from end-expiratory to inspiratory electric activity of the diaphragm (Eadi). The tidal volume will be calculated using data from the ventilator and Eadi acquired using a NAVA (neurally adjusted ventilatory assist) catheter.

    Time frame: Measured from 5 breaths 10 minutes after the application of interventional PEEP level.

  8. Neuromuscular efficiency

    The neuromuscular efficiency will be calculated as the change in transdiaphragmatic pressure (esophageal pressure - gastric pressure) from end-expiration to inspiration divided by the change in electric activity of the diaphragm from end-expiration to inspiration.

    Time frame: This will be calculated from 5 breaths acquired 10 minutes after the application of interventional PEEP level.

  9. Electric activity of the diaphragm

    Electric activity of the diaphragm (Eadi) during end-expiration, inspiration and occlusion manoeuvres will be measured by NAVA (neurally adjusted ventilator assist) catheters in Voltages

    Time frame: Measured during 5 breaths 10 minutes after application of interventional PEEP level. Additionally measured during an occlusion manoeuvre 10-15 minutes after application of interventional PEEP level.

  10. Thickening fraction of the intercostal muscles

    Intercostal muscles will be examined by ultrasound in the cranio-caudal direction at the second intercostal space. The thickening fraction of the intercostal muscles (TFic) will be calculated as the \[ (end-inspiratory intercostal thickness - end-expiratory intercostal thickness) / end-expiratory intercostal thickness) \].

    Time frame: Measured 10 minutes after application of interventional PEEP level

07

Study locations

1 of 2 sites recruiting
  • Central intensivvårdsavdelning, Sahlgrenska University Hospital
    Gothenburg, Västra Götaland County 413 45, Sweden
    Recruiting
  • Thorax intensivvårdsavdelning, Område 6, Sahlgrenska University Hospital, Västra Götalandsregionen
    Gothenburg, Västra Götaland County 413 45, Sweden
    Not yet recruiting
08

References and documents

Individual participant data

Plan to share: No — The acquired swedish ethical permit does not allow for the sharing of data to international researcher without a confidentiality review or the application of a new ethical permit

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07188038
Lead sponsor
Vastra Gotaland Region
Collaborators
Sahlgrenska University Hospital, Göteborg University
Responsible party
Sponsor
First posted
Sep 23, 2025
Start date
Aug 31, 2026
Primary completion
Jul 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Sep 2, 2026

Study contacts

Hannes Widing
Contact
hannes.widing@vgregion.se
0046703957374
Per Persson
Contact
per.persson@gregion.se
Hannes Widing
principal investigator · Anesthesia and intensive care medicine, Område 5, Sahlgrenska University hospital, Västra Götalandsregionen

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion